Burdick Andrew D, Kim Dae J, Peraza Marjorie A, Gonzalez Frank J, Peters Jeffrey M
Department of Veterinary Science and Center for Molecular Toxicology and Carcinogenesis, 312 Life Sciences Building, The Pennsylvania State University, University Park, PA 16802, USA.
Cell Signal. 2006 Jan;18(1):9-20. doi: 10.1016/j.cellsig.2005.07.009. Epub 2005 Aug 16.
The physiological and pharmacological roles of peroxisome proliferator-activated receptor-beta (PPARbeta-also referred to as PPARdelta) are just beginning to emerge. It has recently become clear that PPARbeta has a function in epithelial tissues, but controversy exists due to inconsistencies in the literature. There is strong evidence that ligand activation of PPARbeta can induce terminal differentiation of keratinocytes, with a concomitant inhibition of cell proliferation. However, the role of PPARbeta in keratinocyte-specific apoptosis is less clear. Additionally, the role of PPARbeta in colonic epithelium remains unclear due to conflicting evidence suggesting that ligand activation of PPARbeta can potentiate, as well as attenuate, intestinal cancer. Recent studies revealed that ligand activation of PPARbeta can induce fatty acid catabolism in skeletal muscle and is associated with improved insulin sensitivity, attenuated weight gain and elevated HDL levels thus demonstrating promising potential for targeting PPARbeta for treating obesity, dyslipidemias and type 2 diabetes. Therefore, it becomes critical to determine the safety of PPARbeta ligands. This review focuses on recent literature describing the role of PPARbeta in epithelial tissues and highlights critical discrepancies that need to be resolved for a more comprehensive understanding of how this receptor modulates epithelial homeostasis.
过氧化物酶体增殖物激活受体β(PPARβ,也称为PPARδ)的生理和药理作用才刚刚开始显现。最近已经明确PPARβ在上皮组织中具有功能,但由于文献中的不一致性,仍存在争议。有强有力的证据表明,PPARβ的配体激活可诱导角质形成细胞的终末分化,同时抑制细胞增殖。然而,PPARβ在角质形成细胞特异性凋亡中的作用尚不清楚。此外,由于相互矛盾的证据表明PPARβ的配体激活既可以增强也可以减弱肠道癌症,PPARβ在结肠上皮中的作用仍不清楚。最近的研究表明,PPARβ的配体激活可诱导骨骼肌中的脂肪酸分解代谢,并与改善胰岛素敏感性、减轻体重增加和提高高密度脂蛋白水平相关,因此显示出靶向PPARβ治疗肥胖症、血脂异常和2型糖尿病的潜在前景。因此,确定PPARβ配体的安全性变得至关重要。本综述重点关注描述PPARβ在上皮组织中作用的最新文献,并强调了一些关键差异,这些差异需要解决,以便更全面地了解该受体如何调节上皮稳态。